Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: New insight into CXCR4-FC131 interactions

被引:34
|
作者
Yoshikawa, Yasushi [1 ]
Kobayashi, Kazuya [2 ]
Oishi, Shinya [2 ]
Fujii, Nobutaka [2 ]
Furuya, Toshio [1 ,3 ]
机构
[1] PharmaDesign Inc, Div Res & Dev, Drug Discovery Dept, Chuo Ku, Tokyo 1040032, Japan
[2] Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan
[3] Univ Tokyo, Open Innovat Ctr Drug Discovery, Bunkyo Ku, Tokyo 1130033, Japan
关键词
FC131; CXCR4; GPCR; Docking; Molecular modeling; CHEMOKINE RECEPTOR CXCR4; HIV-1; ENTRY; BINDING; IDENTIFICATION; T140; INHIBITOR; MECHANISM; SDF-1; SCAFFOLDS; AGENTS;
D O I
10.1016/j.bmcl.2012.01.134
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
CXCR4 is a G-protein coupled receptor that is associated with many diseases such as breast cancer metastasis, HIV infection, leukemic disease and rheumatoid arthritis, and is thus considered an attractive drug target. Previously, we identified a cyclic pentapeptide, FC131, that is a potent antagonist for CXCR4. In this study, we constructed a three dimensional model of the CXCR4-FC131 complex. To investigate the backbone flexibility of FC131, we performed molecular dynamics simulations of FC131 based on the NMR structure of FC131, and obtained snapshot structures from the trajectories which were used to model the docking pose of FC131 into CXCR4. Our final model of the CXCR4-FC131 complex is partially different from the X-ray crystal structure of CXCR4-CVX15 and suggests water-mediated interactions. Nevertheless, this docking pose is consistent with the experimental data. We believe our model will aid in the discovery and development of small-molecule antagonists for CXCR4. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2146 / 2150
页数:5
相关论文
共 50 条
  • [41] CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers
    J A Burger
    A Peled
    Leukemia, 2009, 23 : 43 - 52
  • [42] Synthesis and biological evaluation of CXCR4 antagonists as pharmaceutical agents
    Tamamura, H.
    Tsutsumi, H.
    Masuno, H.
    Ogawa, T.
    Hiramatsu, K.
    Araki, T.
    Ueda, S.
    Oishi, S.
    Esaka, A.
    Wang, Z.
    Peiper, S. C.
    Trent, J. O.
    Fujii, N.
    JOURNAL OF PEPTIDE SCIENCE, 2006, 12 : 150 - 150
  • [43] A future perspective on the development of chemokine receptor CXCR4 antagonists
    Tamamura, Hirokazu
    Tsutsumi, Hiroshi
    Nomura, Wataru
    Tanaka, Tomohiro
    Fujii, Nobutaka
    EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (10) : 1155 - 1166
  • [44] HETEROGENEOUS EFFECTS OF CXCR4 ANTAGONISTS ON THE PROLIFERATION OF MYELOMA CELLS
    Kim, H. Y.
    Kim, S. W.
    Hwang, J. Y.
    Lee, H. J.
    Yun, H. J.
    Kim, S.
    Jo, D. Y.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 568 - 569
  • [45] From Insight to Modulation of CXCR4 and ACKR3 (CXCR7) Function
    Smit, Martine J.
    van Muijlwijk-Koezen, Jacqueline E.
    MOLECULAR PHARMACOLOGY, 2019, 96 (06) : 735 - 736
  • [46] Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
    Mamoru Morimoto
    Yoichi Matsuo
    Shuji Koide
    Ken Tsuboi
    Tomoya Shamoto
    Takafumi Sato
    Kenta Saito
    Hiroki Takahashi
    Hiromitsu Takeyama
    BMC Cancer, 16
  • [47] CXCR4, the new innate immunity regulator?
    Smith, Nikaia
    Pietrancosta, Nicolas
    Herbeuval, Jean-Philippe
    M S-MEDECINE SCIENCES, 2017, 33 (8-9): : 711 - 713
  • [48] Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
    Morimoto, Mamoru
    Matsuo, Yoichi
    Koide, Shuji
    Tsuboi, Ken
    Shamoto, Tomoya
    Sato, Takafumi
    Saito, Kenta
    Takahashi, Hiroki
    Takeyama, Hiromitsu
    BMC CANCER, 2016, 16
  • [49] Development of a Novel SPR Assay to Study CXCR4–Ligand Interactions
    Boonen A.
    Singh A.K.
    Van Hout A.
    Das K.
    Van Loy T.
    Noppen S.
    Schols D.
    Biosensors, 2020, 10 (10):
  • [50] The central role of the chemokine receptor, CXCR4, in haemopoietic stem cell transplantation: will CXCR4 antagonists contribute to the treatment of blood disorders?
    Watt, S. M.
    Forde, S. P.
    VOX SANGUINIS, 2008, 94 (01) : 18 - 32